Everything below concerns PPARδ. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
The possible traces could be nuclear remnants, to be sought within the spectral types going from A5 to F2 according to Whitmire and Wright. It could also be a change in the isotopic ratio, due to a stellar engine, or an unusual spectral modulation in the composition of the star.
=== Genetically modified food === In 2015, Ayyadurai published a paper that applied systems biology, which uses mathematical modeling, to predict the chemical composition of genetically modified (GM) soybeans, and whether or not they were substantially equivalent to unmodified soybeans. The paper claimed that GM soybeans have lower levels of the antioxidant glutathione and higher levels of carcinogenic formaldehyde, making the modified soybean substantially different, contrary to previous safety assessments. Shortly after publication, Ayyadurai embarked on a speaking tour of the U.S. At the National Press Club, he said that genetic modification had "fundamentally modified the metabolic system of the soy", disrupting the "beautiful way of detoxifying [formaldehyde]" present in non-GM soy. The European Food Safety Agency evaluated the paper and determined that "the author's conclusions are not supported" due to the lack of information on the input into the model, the fact that the model was not validated and because no measurements of soybeans were made to establish whether GM soy actually contained elevated levels of formaldehyde. Plant scientist Kevin Folta noted that there was "no evidence ever published ... that shows a difference in formaldehyde between GM and non-GM varieties". Ayyadurai later cited the study as evidence of a lack of safety standards for GM foods and bet Monsanto a $10 million building if they could prove that they were safe.
== Clinical benefits == As a first-generation medication, golodirsen is far away from being curative; clinical trial outcomes have demonstrated it to have a marginal effect on ameliorating Duchenne muscular dystrophy pathology. As of December 2019, golodirsen is approved for therapeutic use in the United States, as well as in the countries that automatically recognize the decisions of the US Food and Drug Administration, under the condition that its benefit will be demonstrated in a confirmatory clinical trial.
=== The Black Box === Valve planned on releasing an additional compilation for Windows entitled The Black Box, which would have contained only the three new games released as a part of the Orange Box—Half-Life 2: Episode Two, Portal, and Team Fortress 2. The Black Box was later cancelled for retail and only made available through Steam exclusively to owners of certain ATI graphics cards, who received a voucher for a free copy of The Black Box. During development, the simultaneous release of two game compilation packages with different content combinations was touted by Valve as a new direction for the game industry. Gabe Newell, co-founder of Valve, said, "The Black Box and The Orange Box represent a new approach to publishing multiple products on multiple platforms." After first discontinuing The Black Box, however, Valve released all the new material for individual download via Steam. The Black Box was to be priced US$10 lower than The Orange Box which would have made it $39.95 on PC and $49.95 on console in the U.S. if it used The Orange Box launch price as a baseline. To compensate for the cancellation of The Black Box, Valve offered gift subscriptions to Steam users who had previously purchased Half-Life 2 or Half-Life 2: Episode One and then purchased The Orange Box so that they could give their second copies of those two games as gifts to people added to their Steam Friends list. Still, the cancellation of The Black Box sparked complaints from game critics and consumers alike, unhappy that they were obliged to pay for games that they already owned.
Sources: en.wikipedia.org
== Coupled reactions == Since energy is released when ATP is broken down, energy is required to rebuild or resynthesize it. The building blocks of ATP synthesis are the by-products of its breakdown; adenosine diphosphate (ADP) and inorganic phosphate (Pi). The energy for ATP resynthesis comes from three different series of chemical reactions that take place within the body. Two of the three depend upon the food eaten, whereas the other depends upon a chemical compound called phosphocreatine. The energy released from any of these three series of reactions is utilized in reactions that resynthesize ATP. The separate reactions are functionally linked in such a way that the energy released by one is used by the other. Three processes can synthesize ATP:
=== 1990s === 1994: divests its Waters Chromatography Division to focus on its membrane business 1996: acquires Amicon separation sciences business from W. R. Grace and Company 1997: acquires Tylan General, expanding its gas purification offerings for the microelectronics industry 1999: acquires Bioprocessing Limited, a developer and manufacturer of chromatography
Supporters of continued collecting also point to the greater scientific utility and legacy of museum specimens compared to blood samples or photographs, and argue that collecting for research offers the only source of avian mortality with a positive outcome for birds in terms of the biological knowledge gained. Although taking small blood samples from wild birds is often viewed as a harmless alternative to collecting, it reduces survival by as much as 33% and does not provide the benefits of a voucher specimen. Scientists have pointed out that bird populations represent renewable resources, and that scientific collecting represents only a tiny and non-additive proportion of annual bird mortality. However, examples exist of species whose extinction was directly contributed to by museum collecting (e.g. Guadalupe caracara, ivory-billed woodpecker). The last bird of the extinct Black Mamo from Molokai was shot for collecting.
==== Distribution ==== Labetalol is often classified as a beta blocker with low lipophilicity and hence lower potential for crossing the blood–brain barrier and blood–placenta barrier. This in turn may result in fewer effects in the central nervous system as well as a lower risk of neuropsychiatric side effects. Paradoxically however, labetalol actually shows high lipophilicity. In any case, labetalol, in animals including rats, rabbits, and dogs, was found to cross into the brain in negligible amounts, probably for reasons other than low lipophilicity. On the other hand, the drug has been shown to cross the blood–placenta barrier in humans.
Phage display is a laboratory technique for the study of protein interactions that uses bacteriophages (viruses that infect bacteria) to produce and "display" the proteins on their surfaces. Since the proteins remain attached to the surface of the phage, it is possible to isolate the phages displaying desirable proteins from among very large collections (libraries) of phages, using e.g. other protein or DNA molecules as baits. The DNA of the selected phages can then be sequenced to establish the identity of selected proteins. The phages themselves can be further propagated in bacteria to amplify or diversify the selected protein library, with potential for conducting directed evolution experiments with multiple rounds of selection and diversification. Specifically, a gene encoding a protein of interest is inserted into a phage coat protein gene, causing the phage to "display" the protein on its outside while containing the gene for the protein on its inside. This couples the genotype (gene), phenotype (protein) in the context of an organism (phage) capable of replication. The phages displaying proteins of interest can then be selected using other proteins or DNA sequences in order to e.g., identify natural protein binding partners or antibodies with a high binding affinity. The most common bacteriophages used in phage display are M13 and fd filamentous phage, though T4, T7, and λ phage have also been used.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.